Research Output
Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity
  BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure−activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC 50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

  • Type:

    Article

  • Date:

    17 May 2021

  • Publication Status:

    Published

  • Publisher

    American Chemical Society (ACS)

  • DOI:

    10.1021/acs.jmedchem.1c00230

  • Cross Ref:

    10.1021/acs.jmedchem.1c00230

  • ISSN:

    0022-2623

  • Funders:

    New Funder; Historic Funder (pre-Worktribe)

Citation

Abdel-Maksoud, M. S., El-Gamal, M. I., Lee, B. S., Gamal El-Din, M. M., Jeon, H. R., Kwon, D., …Oh, C. H. (2021). Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity. Journal of Medicinal Chemistry, 64(10), 6877-6901. https://doi.org/10.1021/acs.jmedchem.1c00230

Authors

Monthly Views:

Available Documents